<DOC>
	<DOC>NCT00499642</DOC>
	<brief_summary>This is a randomized, double-blind, placebo- and moxifloxacin (open-label)-controlled, 4-period crossover study.</brief_summary>
	<brief_title>Study Evaluating the Effect of Lecozotan SR on the QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Women and men aged 18 to 55 years inclusive. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12lead electrocardiogram (ECG). History of any clinically important drug allergy. Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>